Refine by
Oncology Product Equipment & Supplies
13 equipment items found
Manufactured by:Eupraxia Pharmaceuticals based inVictoria, BRITISH COLUMBIA (CANADA)
Eupraxia hopes to add 1-2 additional candidates to our pipeline within the next year, including an internally developed oncology product. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
CB-1158 dihydrochloride (INCB01158 dihydrochloride) is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM forrecombinant human arginase 1 andrecombinant human arginase 2, respectively. Immuno-oncology ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
TURALIO (pexidartinib) is an oral small molecule that targets colony stimulating factor 1 receptor (CSF1R), KIT proto-oncogene receptor tyrosine kinase (KIT), and FMS-like tyrosine kinase 3 (FLT3) harboring an internal tandem duplication (ITD) ...
Manufactured by:MiraDx based inLos Angeles, CALIFORNIA (USA)
Radiation therapy is a form of cancer treatment that is used in over 2/3 of cancer patients diagnosed every year. Although generally, radiation is a safe treatment, 5-10% of patients will experience serious side effects from treatment. In addition, some patients respond not only locally to radiation, but also have an immune response that can help them to fight their cancer. Miradx is at the ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
VANFLYTA is a FLT3 inhibitor approved in Japan for the treatment of adult patients with acute myeloid leukemia (AML) that is FLT3-ITD mutation positive, including for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as maintenance monotherapy for newly diagnosed FLT3-ITD positive AML, based on the results of the ...
Manufactured by:The Suremark Company based inMesa, ARIZONA (USA)
RadTat Cross Hair Markers (100 cross hair markers per ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
INJECTAFER (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older who have either intolerance to oral iron or an unsatisfactory response to oral iron; and adult patients with IDA who have non-dialysis dependent chronic kidney ...
Manufactured by:QXMedical based inMontreal, QUEBEC (CANADA)
Biodegradable QXMédical Xpheres Microspheres are the next-generation embolics designed to address the evolving needs in the field of embolization therapy, interventional radiology and interventional radiology ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
ENHERTU (5.4 mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a (or one or more) prior antiHER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the ...
by:Abivax based inParis, FRANCE
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer ...
Manufactured by:ONCOERA | Eraser Medical Co. Ltd. based inKavaklidere/Bornova/Izmir, TURKEY
Disposable Chemotherapy Oncology infusion set is one of our most popular merchandise, it is for Chemotherapy drug infusion in the oncology treatment filed, the product possesses the function of light resistance function, multiple dosing ports, needle free injection site, self priming, it is stable and safe for both nurses and ...
by:Castle Biosciences, Inc. based inFriendswood, TEXAS (USA)
Uveal melanoma, commonly known as ocular or choroidal melanoma, is a rare cancer of the eye with approximately 2,000 patients diagnosed annually in the U.S. At the time of initial diagnosis, approximately 97% of patients are free of metastasis. However, within five years, approximately 30% of patients will develop metastasis – rising to nearly 50% in the following ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology ...